Stem definition | Drug id | CAS RN |
---|---|---|
anti-inflammatory agents, ibufenac derivatives | 1103 | 41340-25-4 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 69.60 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 31, 1991 | FDA | WYETH PHARMS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 81.55 | 13.54 | 125 | 6089 | 250885 | 50348025 |
Interstitial lung disease | 35.54 | 13.54 | 38 | 6176 | 53138 | 50545772 |
Psoriatic arthropathy | 22.02 | 13.54 | 28 | 6186 | 47004 | 50551906 |
Hepatic function abnormal | 19.47 | 13.54 | 22 | 6192 | 32659 | 50566251 |
Cholelithiasis | 16.82 | 13.54 | 22 | 6192 | 37951 | 50560959 |
Beta-N-acetyl-D-glucosaminidase increased | 16.48 | 13.54 | 3 | 6211 | 34 | 50598876 |
Psoriasis | 16.44 | 13.54 | 30 | 6184 | 68970 | 50529940 |
Liver disorder | 15.62 | 13.54 | 21 | 6193 | 37201 | 50561709 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Gastric haemorrhage | 49.80 | 17.12 | 23 | 3215 | 9274 | 29562015 |
Gastrointestinal haemorrhage | 41.18 | 17.12 | 47 | 3191 | 79486 | 29491803 |
Gastric ulcer | 40.80 | 17.12 | 23 | 3215 | 14038 | 29557251 |
Duodenal ulcer | 26.49 | 17.12 | 15 | 3223 | 9223 | 29562066 |
Interstitial lung disease | 26.33 | 17.12 | 32 | 3206 | 57686 | 29513603 |
Atypical femur fracture | 20.32 | 17.12 | 5 | 3233 | 286 | 29571003 |
Erythema multiforme | 18.09 | 17.12 | 11 | 3227 | 7706 | 29563583 |
Metamorphopsia | 17.61 | 17.12 | 5 | 3233 | 497 | 29570792 |
Rectal haemorrhage | 17.13 | 17.12 | 20 | 3218 | 34529 | 29536760 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 69.06 | 13.97 | 111 | 7600 | 237704 | 64253317 |
Interstitial lung disease | 50.00 | 13.97 | 60 | 7651 | 97672 | 64393349 |
Gastric haemorrhage | 42.46 | 13.97 | 24 | 7687 | 13457 | 64477564 |
Gastric ulcer | 37.15 | 13.97 | 30 | 7681 | 30204 | 64460817 |
Gastrointestinal haemorrhage | 30.72 | 13.97 | 56 | 7655 | 132256 | 64358765 |
Duodenal ulcer | 21.37 | 13.97 | 16 | 7695 | 14419 | 64476602 |
Osteonecrosis of external auditory canal | 18.61 | 13.97 | 4 | 7707 | 114 | 64490907 |
Beta-N-acetyl-D-glucosaminidase increased | 14.97 | 13.97 | 3 | 7708 | 60 | 64490961 |
None
Source | Code | Description |
---|---|---|
ATC | M01AB08 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances |
FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
CHEBI has role | CHEBI:35493 | anti-pyretic |
CHEBI has role | CHEBI:50629 | COX-2 inhibitor |
FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D052246 | Cyclooxygenase 2 Inhibitors |
MeSH PA | D016861 | Cyclooxygenase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pain | indication | 22253000 | |
Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
Osteoarthritis | indication | 396275006 | |
Juvenile rheumatoid arthritis | indication | 410795001 | |
Ankylosing spondylitis | off-label use | 9631008 | DOID:7147 |
Tendinitis | off-label use | 34840004 | DOID:971 |
Bursitis | off-label use | 84017003 | DOID:2965 |
Gout | off-label use | 90560007 | DOID:13189 |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Coronary artery bypass graft | contraindication | 232717009 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pregnancy, function | contraindication | 289908002 | |
Cardiovascular event risk | contraindication | 395112001 | |
Smokes tobacco daily | contraindication | 449868002 |
Species | Use | Relation |
---|---|---|
Dogs | Pain and inflammation associated with osteoarthritis | Indication |
Product | Applicant | Ingredients |
---|---|---|
EtoGesic Tablets | Boehringer lngelheim Animal Health USA Inc. | 1 |
Etogesic Sterile Injectable Solution | Boehringer lngelheim Animal Health USA Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.95 | acidic |
pKa2 | 11.17 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 5.70 | CHEMBL | CHEMBL | |||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.58 | DRUG MATRIX |
ID | Source |
---|---|
4019559 | VUID |
N0000147659 | NUI |
D00315 | KEGG_DRUG |
4019559 | VANDF |
C0059865 | UMLSCUI |
CHEBI:4909 | CHEBI |
CHEMBL622 | ChEMBL_ID |
DB00749 | DRUGBANK_ID |
D017308 | MESH_DESCRIPTOR_UI |
3308 | PUBCHEM_CID |
7185 | IUPHAR_LIGAND_ID |
3715 | INN_ID |
2M36281008 | UNII |
24605 | RXNORM |
4707 | MMSL |
8937 | MMSL |
d00851 | MMSL |
003587 | NDDF |
108510003 | SNOMEDCT_US |
386860005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1118 | TABLET, FILM COATED, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1118 | TABLET, FILM COATED, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1122 | TABLET, FILM COATED, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1122 | TABLET, FILM COATED, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7172 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7172 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0675 | TABLET, COATED | 400 mg | ORAL | ANDA | 26 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0687 | TABLET, COATED | 500 mg | ORAL | ANDA | 26 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-862 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
ETODOLAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-092 | TABLET | 400 mg | ORAL | ANDA | 30 sections |
ETODOLAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-488 | CAPSULE | 300 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-497 | TABLET, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 28 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-498 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 28 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-499 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 28 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-049 | CAPSULE, GELATIN COATED | 300 mg | ORAL | ANDA | 27 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-050 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-043 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-044 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-711 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-052 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-121 | CAPSULE | 300 mg | ORAL | ANDA | 14 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-404 | CAPSULE | 200 mg | ORAL | ANDA | 26 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-405 | CAPSULE | 300 mg | ORAL | ANDA | 26 sections |
ETODOLAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-511 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
Etodolac | Human Prescription Drug Label | 1 | 42799-111 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 25 sections |
Etodolac | Human Prescription Drug Label | 1 | 42799-112 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-578 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 29 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-578 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 29 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-671 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 29 sections |
Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-671 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 29 sections |